激动型抗 TNF 受体抗体与 FcγRIIB 共结合的一般要求。
A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies.
出版信息
Cell Cycle. 2012 Sep 15;11(18):3343-4. doi: 10.4161/cc.21842. Epub 2012 Aug 23.
Abstract
Comment on: Li F, et al. Proc Natl Acad Sci USA 2012; 109:10966-71.
摘要
评论
李 F，等。美国国家科学院院刊 2012；109:10966-71。
相似文献
1
A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies.
Cell Cycle. 2012 Sep 15;11(18):3343-4. doi: 10.4161/cc.21842. Epub 2012 Aug 23.
2
Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo.
Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19501-6. doi: 10.1073/pnas.1319502110. Epub 2013 Nov 11.
3
Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement.
Proc Natl Acad Sci U S A. 2012 Jul 3;109(27):10966-71. doi: 10.1073/pnas.1208698109. Epub 2012 Jun 20.
4
FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.
Cancer Immunol Immunother. 2013 May;62(5):941-8. doi: 10.1007/s00262-013-1398-6. Epub 2013 Mar 31.
5
Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
J Biol Chem. 2016 Dec 30;291(53):27134-27146. doi: 10.1074/jbc.M116.757773. Epub 2016 Nov 17.
6
Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.
Hum Antibodies. 2017;25(3-4):87-109. doi: 10.3233/HAB-160308.
7
Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.
Science. 2011 Aug 19;333(6045):1030-4. doi: 10.1126/science.1206954.
8
Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies.
Mol Immunol. 2008 Sep;45(15):3926-33. doi: 10.1016/j.molimm.2008.06.027. Epub 2008 Aug 8.
9
Allergen-specific IgG antibody signaling through FcγRIIb promotes food tolerance.
J Allergy Clin Immunol. 2018 Jan;141(1):189-201.e3. doi: 10.1016/j.jaci.2017.03.045. Epub 2017 May 4.
10
A recombinant tumor necrosis factor-alpha p80 receptor:Fc fusion protein decreases circulating bioactive tumor necrosis factor-alpha but not lung injury or mortality during immunosuppression-related gram-negative bacteremia.
J Crit Care. 1997 Mar;12(1):28-38. doi: 10.1016/s0883-9441(97)90023-x.
引用本文的文献
1
Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer.
Cancer Cell. 2025 Aug 1. doi: 10.1016/j.ccell.2025.07.013.
2
CD32B1, a versatile non-signaling antibody-binding scaffold for enhanced T cell adhesion to tumor stromal cognate antigens.
Front Immunol. 2025 Feb 10;16:1398757. doi: 10.3389/fimmu.2025.1398757. eCollection 2025.
3
Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations.
J Immunother Cancer. 2024 Jul 4;12(7):e008677. doi: 10.1136/jitc-2023-008677.
4
FcγR requirements and costimulatory capacity of Urelumab, Utomilumab, and Varlilumab.
Front Immunol. 2023 Jul 27;14:1208631. doi: 10.3389/fimmu.2023.1208631. eCollection 2023.
5
TNFR2 antagonist and agonist: a potential therapeutics in cancer immunotherapy.
Med Oncol. 2022 Sep 29;39(12):215. doi: 10.1007/s12032-022-01772-2.
6
Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer.
Sci Transl Med. 2021 May 19;13(594). doi: 10.1126/scitranslmed.abd1346.
7
OX40 as a novel target for the reversal of immune escape in colorectal cancer.
Am J Transl Res. 2021 Mar 15;13(3):923-934. eCollection 2021.
8
Domain binding and isotype dictate the activity of anti-human OX40 antibodies.
J Immunother Cancer. 2020 Dec;8(2). doi: 10.1136/jitc-2020-001557.
9
Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility.
Nat Commun. 2019 Sep 27;10(1):4206. doi: 10.1038/s41467-019-12097-6.
10
HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality.
J Immunother Cancer. 2019 Jul 19;7(1):191. doi: 10.1186/s40425-019-0671-4.
本文引用的文献
1
Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement.
Proc Natl Acad Sci U S A. 2012 Jul 3;109(27):10966-71. doi: 10.1073/pnas.1208698109. Epub 2012 Jun 20.
2
Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.
Science. 2011 Aug 19;333(6045):1030-4. doi: 10.1126/science.1206954.
3
Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody.
J Immunol. 2011 Aug 15;187(4):1754-63. doi: 10.4049/jimmunol.1101135. Epub 2011 Jul 8.
4
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.
Cancer Cell. 2011 Jan 18;19(1):101-13. doi: 10.1016/j.ccr.2010.11.012.
5
Anti-tumor effects of depleting and non-depleting anti-CD27 monoclonal antibodies in immune-competent mice.
Biochem Biophys Res Commun. 2010 Mar 19;393(4):829-35. doi: 10.1016/j.bbrc.2010.02.092. Epub 2010 Feb 18.
6
Fcgamma receptors as regulators of immune responses.
Nat Rev Immunol. 2008 Jan;8(1):34-47. doi: 10.1038/nri2206.
7
Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors.
Blood. 2006 Jul 15;108(2):705-10. doi: 10.1182/blood-2005-11-4607. Epub 2006 Mar 21.
8
Signalling pathways of the TNF superfamily: a double-edged sword.
Nat Rev Immunol. 2003 Sep;3(9):745-56. doi: 10.1038/nri1184.
9
Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics.
J Immunol. 2003 Jul 15;171(2):562-8. doi: 10.4049/jimmunol.171.2.562.
10
Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4.
J Immunol. 2001 Apr 15;166(8):4891-8. doi: 10.4049/jimmunol.166.8.4891.
Zotero 插件